Idexx Laboratories IDXX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 62.1%+0.3pp | 61.8%+0.1pp | 61.7%+0.2pp | 61.5%+0.3pp | 61.3%+0.2pp | |
| Operating margin | 31.6%0.0pp | 31.6%+0.3pp | 31.3%+0.3pp | 31.1%+1.9pp | 29.1%+0.2pp | |
| Net margin | 24.6%0.0pp | 24.6%0.0pp | 24.7%+0.2pp | 24.4%+1.6pp | 22.8%0.0pp | |
| EBITDA margin | 35%0.0pp | 35%+0.3pp | 34.7%+0.2pp | 34.5%+1.9pp | 32.6%+0.3pp | |
| Free cash flow margin | 24.4%-0.2pp | 24.6%+1.4pp | 23.1%+3.7pp | 19.4%-2.1pp | 21.6%+0.8pp | |
| Returns | ||||||
| Return on equity | 72.9%+6.7pp | 66.2%+1.6pp | 64.6%-0.2pp | 64.9%+5.5pp | 59.3%+1.7pp | |
| Return on assets | 33.2%+1.3pp | 31.9%+1.4pp | 30.5%+1.3pp | 29.2%+2.0pp | 27.3%+0.2pp | |
| Return on invested capital | 56.9%+3.1pp | 53.8%+2.0pp | 51.8%+0.8pp | 51%+5.6pp | 45.4%-0.9pp | |
| Efficiency | ||||||
| Asset turnover | 1.3×+0.1× | 1.3×+0.1× | 1.2×0.0× | 1.2×0.0× | 1.2×0.0× | |
| Inventory turnover | 4.3×0.0× | 4.3×+0.2× | 4.1×+0.1× | 4×+0.1× | 3.9×-0.1× | |
| Liquidity | ||||||
| Current ratio | 1.1×-0.1× | 1.2×+0.1× | 1.2×+0.1× | 1.1×0.0× | 1.2×-0.2× | |
| Quick ratio | 0.8×-0.1× | 0.9×0.0× | 0.9×+0.1× | 0.8×0.0× | 0.8×-0.1× | |
| Cash ratio | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.1×0.0× | 0.1×-0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.4×0.0× | 0.4×-0.1× | 0.4×0.0× | 0.5×-0.1× | 0.5×0.0× | |
| Debt-to-assets | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Net debt / EBITDA | 0.2×0.0× | 0.3×0.0× | 0.3×0.0× | 0.4×-0.1× | 0.4×+0.1× | |
| Interest coverage | 36.1×+1.1× | 35×-0.2× | 35.2×-1.6× | 36.7×-0.3× | 37×+0.9× | |
| Per Share | ||||||
| Book value per share | $19.41-2.0% | $19.81+2.4% | $19.35+7.4% | $18.01+1.9% | $17.68-7.8% | |
| Valuation | ||||||
| Market capitalization | $44.63B-17.4% | $54.02B+5.7% | $51.11B+19.8% | $42.66B+25.4% | $34.03B+0.5% | |
| Enterprise value | $45B-17.3% | $54.42B+5.5% | $51.56B+19.5% | $43.16B+24.7% | $34.61B+0.9% | |
| Price / earnings | 40.7×-10.2× | 51×+1.2× | 49.7×+6.5× | 43.3×+5.3× | 38×-0.1× | |
| Price / sales | 10×-2.5× | 12.6×+0.3× | 12.3×+1.7× | 10.6×+1.9× | 8.7×0.0× | |
| Price / book | 28.7×-5.0× | 33.7×+0.9× | 32.7×+3.5× | 29.2×+5.7× | 23.5×+2.3× | |
| EV / EBITDA | 28.9×-7.2× | 36.2×+0.5× | 35.7×+4.7× | 31×+3.9× | 27×-0.2× | |
| EV / sales | 10.1×-2.5× | 12.6×+0.3× | 12.4×+1.7× | 10.7×+1.9× | 8.8×0.0× | |
| Free cash flow yield | 2.4%+0.5pp | 2%+0.1pp | 1.9%0.0pp | 1.8%-0.7pp | 2.5%+0.1pp | |
| Earnings yield | 2.5%+0.5pp | 2%0.0pp | 2%-0.3pp | 2.3%-0.3pp | 2.6%0.0pp | |
| PEG ratio | 1.8×-0.8× | 2.6×0.0× | 2.7×+0.1× | 2.6×-9.0× | 11.6×+4.1× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Idexx Laboratories's profit margins?
- Idexx Laboratories (IDXX) runs a 62.1% gross margin and a 31.6% operating margin, with a 24.6% net margin.
- Where do Idexx Laboratories's ratios come from?
- Every ratio is computed from Idexx Laboratories's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
